Vosoritide comment watch save

  • TRADE NAME: Voxzogo (BioMarin)
  • INDICATIONS: Growth deficiency in pediatric patients with achondroplasia.
  • CLASS: Natriuretic, Polypeptide
  • HALF-LIFE: 21–28 minutes
  • FDA APPROVAL DATE: 11/19/2021
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    None known
  • PREGNANCY: No available data on vosoritide use in pregnant women.

Please login to view the rest of this drug profile.

Page last updated 01/27/2025

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top